CNN —A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced Thursday.
Generalized anxiety order is characterized by excessive, ongoing thoughts that are difficult to control and interfere with day-to-day activities.
Anxiety is one of the most common mental disorders in the US, according to the Anxiety and Depression Association of America.
The MM120 study, however, was accomplished without the use of psychotherapy during the session.
So that’s a critical difference.”Most adverse effects in the study were rated as mild to moderate by participants, occurring mostly on the day of the study, Karlin said.
Persons:
“, ”, Daniel Karlin, MindMed’s MM120, ” Karlin, buspirone —, Karlin, David Nutt, Nutt, Dr, Gabriella Gobbi, Timothy Leary, Richard Alpert, Eddie Adams, Leary, Richard Nixon
Organizations:
CNN, US Food and Drug Administration, Medicine Inc, Tufts University School of Medicine, FDA, Depression Association of America, Unit, Imperial College London’s, McGill University Health Centre, Canada, Therapeutics, Mental Health, Harvard University, Harvard, League for Spiritual, Woodstock
Locations:
Boston, United States, Montreal, New York, Vietnam